1. DOP37 Efficacy and safety of 3 years of continuous ozanimod treatment: an interim analysis of the True North open-label extension study. (30th January 2023) Authors: Danese, S; Abreu, M T; Wolf, D C; Canavan, J B; Jain, A; Wu, H; Petersen, A; Charles, L; Panaccione, R; Afzali, A Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i101 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. DOP43 Rapidity of ozanimod-induced symptomatic response and remission in patients with moderately to severely active Ulcerative Colitis: Results from the induction period of True North. (21st January 2022) Authors: Siegmund, B; Axelrad, J; Pondel, M; Osterman, M T; Ahmad, H A; Memaj, A; Regueiro, M; Armuzzi, A; Afzali, A Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i092 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. DOP44 Long-term use of ozanimod in patients with moderately to severely active Ulcerative Colitis. (21st January 2022) Authors: Danese, S; Colombel, J F; Ponich, T; Jovanovic, I; Bossuyt, P; Longman, R; Alekseeva, O; Petersen, A; Chitkara, D; Marta, C; Charles, L; Rubin, D T; Afzali, A; Loftus, E V; Wolf, D C Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i093 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. OP24 Clinical efficacy and safety of guselkumab maintenance therapy in patients with moderately to severely active Crohn's Disease: Week 48 analyses from the phase 2 GALAXI 1 study. (21st January 2022) Authors: Danese, S; Panaccione, R; Rubin, D T; Sands, B E; Reinisch, W; D'Haens, G; Panés, J; Gonzalez, S; Weisel, K; Sahoo, A; Frustaci, M E; Yang, Z; Sandborn, W J; Afzali, A; Hisamatsu, T; Andrews, J M; Feagan, B Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i026 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. OP28 The effect of guselkumab induction therapy on early clinical outcome measures in patients with Moderately to Severely Active Crohn's Disease: Results from the phase 2 GALAXI 1 study. (27th May 2021) Authors: Danese, S; Sandborn, W J; Feagan, B G; Weisel, K; Gonzalez, S; Frustaci, M E; Yang, Z; Johanns, J; Germinaro, M; Afzali, A; Andrews, J M; D'Haens, G; Hisamatsu, T; Panaccione, R; Reinisch, W; Rubin, D T; Sands, B E; Panes, J Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S027 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P393 Patient and physician perspectives on the management of inflammatory bowel disease: Role of steroids in the context of biologic therapy. (15th January 2020) Authors: Afzali, A; Armuzzi, A; Bouhnik, Y; Bressler, B; Hart, A; Rubin, D; Sans, M; Siegmund, B; Sninsky, D Journal: Journal of Crohn's and colitis Issue: Volume 14(2020)Supplement 1 Page Start: S366 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. P405 Long-term safety of 3 years of ozanimod in moderately to severely active ulcerative colitis: an interim analysis of the True North open-label extension. (30th January 2023) Authors: Panaccione, R; Danese, S; Wolf, D C; Canavan, J B; Jain, A; Wu, H; Petersen, A; Charles, L; Afzali, A; Abreu, M T Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i534 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. P464 Effects of ozanimod on histologic remission and mucosal healing over 3 years of continuous treatment in patients with ulcerative colitis. (30th January 2023) Authors: Panaccione, R; Danese, S; Wolf, D C; Canavan, J B; Jain, A; Wu, H; Petersen, A; Afzali, A; Abreu, M T Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i591 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. P473 Corticosteroid-free clinical remission rates with guselkumab maintenance therapy in patients with moderately to severely active Crohn's disease: Week 48 analyses from the phase 2 GALAXI 1 study. (30th January 2023) Authors: D'Haens, G; Afzali, A; Filip, R; Rolim, A; Terry, N A; Salese, L; Sahoo, A; Frustaci, M E; Yang, Z; Andrews, J M; Danese, S; Hisamatsu, T Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i601 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. P539 Unmet needs in advanced therapy-naïve (ATN) and advanced therapy-experienced (ATE) moderate-to-severe (mod-sev) ulcerative colitis (UC) patients in the United States (US). (27th May 2021) Authors: Afzali, A; Kakehi, S; Lapensee, K; Lukanova, R; Hennessy, F; Knight, H; Singh, K Journal: Journal of Crohn's and colitis Issue: Volume 15(2021)Supplement 1 Page Start: S510 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗